Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SRZN vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EQ Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–4 Matrix Metrics)

EQ Overall Winner 6-Pillar Tally: SRZN 2 – 3 EQ (1 Tie) Matrix Metrics: SRZN 4 – 5 EQ

As of Nov 20, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas EQ carries 48.6/100 (HOLD) at $1.06 (1.5x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: EQ earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. SRZN 36.0/100 SELL) and 1.54β · 89% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs EQ
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93
EQ NASDAQ Head-to-Head Winner
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.06
-5.36% 1D
Market Cap $92.2M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.54β · 89% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 29.0 Fund 55.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.3%), weak momentum, RSI 34
RSI-14: 33.7 · SMA20: $1.32 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 EQ)

Columns: Metric · SRZN · EQ
1. Valuation Multiples EQ
Forward P/E N/M 1.5x
Trailing P/E N/M 1.5x
PEG Ratio N/M N/M
EV / Revenue 52.1x 8.1x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% -52.3%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $4.4M
Market Cap $642.7M $92.2M
3. Profitability & Quality EQ
Gross Margin N/A 100.0%
Operating Margin -485.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -59.0%
4. Balance Sheet & Cash Flow EQ
Cash Generation (TTM) -$31M -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $57M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (13th %ile) 261.3% (100th %ile)
Put/Call OI Skew 21.00x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (4) vs EQ (5)
Institutional Metric SRZN EQ Criterion Row Edge
Market Capitalization
Scale
$642.7M $92.2M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
+408.6% -52.3% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% 0.0% Higher Margin EQ
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -59.0% Higher ROE EQ
52-Week Range Position
Momentum
63% ($13–$38) 9% ($1–$4) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.29β · 73% Vol 1.54β · 89% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 48.6 / 100 (HOLD) Higher Composite EQ
Trailing 12M Revenue (USD)
Operating Scale
$11M $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 52.1x EV/Rev N/M PEG · 8.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +27.06 pp
SRZN: +10.52% · EQ: -16.54%
3M Horizon SRZN +70.55 pp
SRZN: +18.73% · EQ: -51.82%
6M Horizon SRZN +61.03 pp
SRZN: +7.93% · EQ: -53.1%
1Y Horizon SRZN +105.86 pp
SRZN: +110.81% · EQ: +4.95%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue EQ Revenue SRZN Op. Margin EQ Op. Margin Margin Leader
FY2022 $10M $20M -354.7% -393.9% SRZN
FY2023 N/A $40M N/A -40.2% EQ
FY2024 $10M $40M -239.7% -20.1% EQ
FY2025 $0M N/A -1210.6% N/A SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $92.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs EQ Key Questions & Quantitative Answers

As of Nov 20, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas EQ carries 48.6/100 (HOLD) at $1.06 (1.5x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: EQ earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. SRZN 36.0/100 SELL) and 1.54β · 89% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), SRZN cumulative revenue shifted +0.0% while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 8.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.54β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.